Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

PURPOSE: Veliparib is an oral inhibitor of poly(ADP-ribose) polymerase enzyme. Combination of veliparib and temozolomide was well-tolerated and demonstrated clinical activity in older patients with relapsed or refractory acute myeloid leukemia (AML) or AML arising from pre-existing myeloid malignanc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Chemother Pharmacol
Autores principales: Singh, Renu, Mehrotra, Shailly, Gopalakrishnan, Mathangi, Gojo, Ivana, Karp, Judith E., Greer, Jacqueline M., Chen, Alice, Piekarz, Richard, Kiesel, Brian F., Gobburu, Jogarao, Rudek, Michelle A., Beumer, Jan H.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6404524/
https://ncbi.nlm.nih.gov/pubmed/30456480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3731-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares